Overexpression of the immunosuppressive protein B7‐H4 inhibits T‐cell activation and tumor adaptive immune response.[14, 15, 16, 17] Intriguingly, our studies also revealed the concurrent upregulation of TROP2, the target receptor for the antibody‐drug conjugate sacituzumab govitecan, in patients with elevated levels of B7‐H4, suggesting the potential connection between B7‐H4 with the therapeutic effectiveness of SG. This evidence concerns the gene TACSTD2 and neoplasm.